Roche receives FDA approval for companion diagnostic tests to identify patients with HER2-positive metastatic gastroesophageal adenocarcinoma eligible for ZIIHERA

The PATHWAY HER2 (4B5) test and VENTANA HER2 Dual ISH DNA Probe Cocktail help identify HER2-positive metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma. Differential diagnosis of these cancers, often aggressive and diagnosed at an advanced stage, is critical to...